Switching to tenofovir alafenamide for nucleos(t)ide analogue-experienced patients with chronic hepatitis B: week 144 results from a real-world, multi-centre cohort study.

Publication Year: 2022

DOI:
10.1111/apt.17107

PMCID:
PMC9543913

PMID:
35735794

Journal Information

Full Title: Aliment Pharmacol Ther

Abbreviation: Aliment Pharmacol Ther

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Gastroenterology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Declaration of personal interests : Ogawa E has received research grants from Gilead Sciences and speaker fees from Gilead Sciences and AbbVie. Other authors declare that they have no conflicts of interest. Declaration of funding interests : This work was funded by Gilead Sciences."

Evidence found in paper:

"Declaration of personal interests: Ogawa E has received research grants from Gilead Sciences and speaker fees from Gilead Sciences and AbbVie. Other authors declare that they have no conflicts of interest. Declaration of funding interests: This work was funded by Gilead Sciences."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025